An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)

Trial Profile

An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; Registrational
  • Acronyms SAKURA-3
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 04 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Nov 2017 According to a Revance Therapeutics media release, the company expects to complete the study in the second half of 2018.
    • 03 Nov 2017 According to a Revance Therapeutics media release, the company has completed enrollment of more than 2,100 subjects at multiple sites in the United States and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top